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Galectin-1 is an endogenous immunoregulatory lectin-type protein. Its most important effects
are the inhibition of the differentiation and cytokine production of Th1 and Th17 cells, and
the induction of apoptosis of activated T-cells. Galectin-1 has been identified as a key molecule
in antitumor immune surveillance, and data are accumulating about the pathogenic role of its
deficiency, and the beneficial effects of its administration in various autoimmune disease
models. Initial animal and human studies strongly suggest deficiencies in both galectin-1
production and responsiveness in systemic lupus erythematosus (SLE) T-cells. Since lupus
features widespread abnormalities in T-cell activation, differentiation and viability, in this
review the authors wished to highlight potential points in T-cell signalling processes that
may be influenced by galectin-1. These points include GM-1 ganglioside-mediated lipid raft
aggregation, early activation signalling steps involving p56Lck, the exchange of the CD3
z-ZAP-70 to the FcRg-Syk pathway, defective mitogen-activated protein kinase pathway acti-
vation, impaired regulatory T-cell function, the failure to suppress the activity of interleukin
17 (IL-17) producing T-cells, and decreased suppression of the PI3K-mTOR pathway by
phosphatase and tensin homolog (PTEN). These findings place galectin-1 into the group of
potential pathogenic molecules in SLE. Lupus (2017) 26, 339–347.
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Introduction
Systemic lupus erythematosus (SLE) is one of the
most common and devastating systemic auto-
immune diseases.1 Clinical manifestations are very
diverse, including the most frequent symptoms of
polyarthritis and various skin manifestations.2
Furthermore, glomerulonephritis, central and per-
ipheral nervous system pathology, inﬂammation in
the serous membranes, lung, muscles, eye and car-
diovascular system, and severe blood cytopenias
also develop frequently.3–6 The disease is character-
ized by very complex immune dysregulation,
including T- and B-cell functional alterations that
eventually lead to the loss of peripheral immune
tolerance.7,8
Over the last decades, focus has shifted from
B-cell pathologies towards T-cells, which are the
main mediators of B-cell activation and autoanti-
body production, producers of proinﬂammatory
cytokines, and important components of the
inﬂammatory cell inﬁltrate in the target organs.9
Galectin-1 (Gal-1) has emerged as an important
immunoregulatory molecule that exerts its action
through the control of T-cell diﬀerentiation and
activation, Th1- and Th17-cell speciﬁc apoptosis
induction, and the regulation of the communication
between antigen-presenting cells and T-cells.10–14
Consequently, Gal-1 deﬁciency has been found to
promote clinical symptoms of autoimmune diseases
in animal models,15 and treatment with Gal-1
proved to be beneﬁcial in these models.16–20 In
view of the explored eﬀects of Gal-1 on T-cell func-
tions, viability and regulation of autoimmune
pathologies, it is surprising that data on the poten-
tial role of Gal-1 in SLE are very limited. The pur-
pose of this review is to identify potential points in
T-cell functional alterations in SLE that may be
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related to Gal-1 dysregulation, speciﬁcally in rela-
tion to T-cell apoptosis and anergy,13 and modula-
tion of the inﬂammatory environment.21
Overview of the immunoregulatory
effects of galectin-1
Gal-1 is a member of a family of b-galactoside bind-
ing lectins with speciﬁc aﬃnity to terminal N-acetyl-
lactosamine motifs on multi-antennary cell surface
N-glycans.21 Gal-1 binding structures are abun-
dantly present on almost all cell types, and partici-
pate in cell adhesion,22 migration,23 and signal
transduction.24 Here, we mainly focus on the eﬀect
of Gal-1 on T-cells. Cell surface Gal-1-binding gly-
coconjugates on T-cells, including CD45,25 CD7,26
GM1 ganglioside,27 and several others, are all
important signal transmitting molecules regulating
T-cell functions. Gal-1 is also expressed on stromal
cells28 and activated endothelial cells29 in lymphoid
organs and at sites of inﬂammation.30
In early experiments, soluble, recombinant
Gal-1 (rGal-1) was used in high concentration (29–
580mg/ml)21 for examination of its T-cell regulatory
eﬀects.However, due to its high aﬃnity to cell surface
or extracellular matrix glycoconjugates, Gal-1 binds
to its neighbouring ligands immediately after secre-
tion.31,32 Consequently, physiologically, Gal-1 does
not occur in soluble form, as its very low serum con-
centration (4–10 ng/ml)33,34 indicates. Therefore,
recently, Gal-1 secreting cells have been used as the
source of the protein in ex vivo experiments,13 repre-
senting a more physiological occurrence of Gal-1.
One of the major eﬀects of Gal-1 is the induction
of apoptosis of the activated T-cell subpopulations
Th1 and Th17,11 whereas Th2 and Treg cell func-
tions are promoted by Gal-1.11,35 The mechanism of
Gal-1-triggered cell death has extensively been stu-
died in vitro.12,36–40 Stimulation of apoptosis
requires the presence of Lck and ZAP70 kinases,39,40
release of ceramide,37 decrease of mitochondrial
membrane potential and caspase activation38
(Figure 1) when triggered with a lower concentration
of soluble (20 mg/ml)20,38 or cell-derived Gal-1.13,41
Soluble Gal-1 in higher concentration (500 mg/ml)
also induces apoptosis of T-cell lines or activated
T-cells in vitro;38,41 however, this cell death can be
distinguished from that due to low-concentration or
cell-bound Gal-1 by the lack of caspase activation
and the requirement of endonuclease G for DNA
degradation.38,41 Apoptosis induced by cell-bound
Gal-1 requires direct interaction between activated
T-cells and the Gal-1 presenting cells or extracellular
matrix.12,32 Accordingly, mesenchymal stromal cells
(MSCs), a type of strongly immunosuppressive mul-
tipotent stem cells,42,43 or tumour cells expressing
and secreting abundant Gal-1 eﬀectively induce
death of activated T-cells in vitro through intimate
cell–cell interaction.12,13,32 In contrast, when the
eﬀector (Gal-1 secreting) and target (activated T
lymphocyte) cells are physically separated by a
semi-permeable membrane (Transwell), no apop-
tosis occurs.12,32 Moreover, the systemic immuno-
suppressive activity of MSCs in vivo does not
depend on their Gal-1 expression, as shown by oval-
bumin-induced delayed type hypersensitivity or type
I diabetes models,32,44 again highlighting the require-
ment for direct cell interaction.
Established Gal-1 binding cell surface glycocon-
jugates on T-cells, including CD7,26 CD4525 and
GM1 ganglioside,41,45 have emerged as key initi-
ators of the signal transduction pathways, although
with rather controversial conclusions. The trans-
membrane receptor tyrosine phosphatase, CD45,
has been identiﬁed as the major Gal-1 binding pro-
tein,25,41 and was initially regarded as the main
signal transmitting receptor for Gal-1.41,46 It has
since been shown to be dispensable.25,26 Indeed,
CD45-deﬁcient Jurkat cells are as sensitive to
Gal-1 induced apoptosis as CD45 expressing coun-
terparts,25 and CD45 is not co-internalized with
Gal-1.47 On the other hand, CD7 has been impli-
cated in Gal-1 mediated T-cell death,26 and CD4þ
CD7- T-cells in Se´zary syndrome were shown to be
resistant to Gal-1 mediated apoptosis.48
Furthermore, CD7 is co-internalized with Gal-1.47
The glycosphingolipid GM1 ganglioside is an
important component of the lipid microdomains,
which fundamentally participate in signalling pro-
cesses, and GM1 is currently regarded as one of the
key Gal-1 binding glycoconjugates.40,47,49
Accordingly, T-cells with low surface GM1-gang-
lioside are remarkably less sensitive to Gal-1
induced cell death than those with high GM1.40
Presumably, this is due to the insuﬃcient mem-
brane localization and activation of Lck, a central
non-receptor tyrosine kinase in Gal-1 triggered
signal transduction for T-cell apoptosis.40
Gal-1 does not only regulate the viability of T-
cells but also modulates their cytokine production.
Treatment of T-cells with Gal-1 decreases the level
of pro-inﬂammatory cytokines such as tumour
necrosis factor (TNF)a, interferon (IFN)g, IL-1b
and IL-222 and upregulates anti-inﬂammatory cyto-
kines such as IL-10, thereby promoting the diﬀer-
entiation of naive CD4þ lymphocytes to the Treg
lineage.50,51
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Gal-1 also blocks inﬁltration of T-cells into tis-
sues, and its low expression by Langerhans cells in
psoriatic skin coincides with the accumulation of
CD8þ cells in the area.52
All of these in vitro results may explain the in vivo
eﬀects of Gal-1 as conﬁrmed by experimental animal
models of several diseases, such as nephrotoxic
serum nephritis,17 experimental colitis,18 lupus,19
collagen-induced arthritis20 and graft-versus-host
disease.16,36 Gal-1 has consequently emerged as an
eﬀective therapeutic tool in these disease models.
However, it must be noted that in such disease
models, soluble Gal-1 has been used in very high
doses (1 mg/kg/day),17,18 which was probably
necessary because of its rapid binding to non-targets
and its rapid internalization into the target cells.20
All of the above-cited studies have focused on the
eﬀects of extracellular Gal-1 on T-cells when added
in soluble form or presented on neighbouring cells.
However, T-cells themselves express Gal-1 when
activated.13 The role of intracellular Gal-1 induced
during T-cell activation is still insuﬃciently
explored. Some researchers have argued that Gal-1
was secreted and aﬀected the T-cell function in an
autocrine fashion in vitro using highly concentrated
cell culture supernatants.53 However, in these experi-
ments Gal-1 might have emanated from dead cells as
a cytoplasmic protein in the cell culture system with-
out active secretion. In contrast, we showed that
Gal-1 remains intracellular, and the de novo synthe-
sized Gal-1 contributed to the sensitivity of T-cells to
the apoptotic eﬀect of extracellular Gal-1.13
Possible roles of galectin-1 in T-cell dysfunction
in SLE: Current knowledge
In SLE-prone (NZBxNZW)F1 mice, administra-
tion of rGal-1 ameliorates the symptoms of the
Figure 1 Mechanism of Gal-1 induced T-cell apoptosis.
Gal-1 binds to an unidentified receptor on T-cells and triggers raft reorganization. The signal induces tyrosine phosphorylation,
which requires functional p56lck and ZAP70. Ceramide is released, downregulating anti-apoptotic Bcl-2 and leading to the sub-
sequent depolarization of the mitochondria. This first activates initiator caspase-9, then effector caspase-3. Proteins and nuclear
DNA are broken down. Solid arrows show steps that have been verified in Blasko´ et al.38 Dashed arrows show steps that have been
suggested or proved elsewhere.
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disease, including a decrease of pathological
lymphocyte activation, serum anti-dsDNA anti-
body production, and incidence of proteinuria,
and the elevation of survival rate.19 In addition,
rGal-1-treated mice display a higher frequency of
Foxp3 expression, consistent with the increase of
regulatory T-cell prevalence. Ex vivo, T-cells from
mice treated with rGal-1 exhibit less proliferation in
response to TCR stimulation; furthermore, these
cells are less eﬃcient at lipid raft clustering in
response to TCR/CD28 engagement.19 These ﬁnd-
ings indicate a potential role of Gal-1 as a molecule
that may correct multiple components of the dysre-
gulated T-cell function and improve the clinical
course of the disease in mice.
The ﬁrst human studies have focused on the
presence of autoantibodies to Gal-1 in SLE
patients.54 While these data showed a diﬀerence
between SLE patients and healthy controls, our
results (unpublished) and another study did not
conﬁrm this ﬁnding.55
We have shown that activated T-cells from SLE
patients produce signiﬁcantly less Gal-1 than those
of healthy controls.13 Since the expression of intra-
cellular Gal-1 regulates the sensitivity of T-cells to
the apoptotic eﬀect of extracellular Gal-1, SLE T-
cells do not respond with cell death to extracellular
Gal-1.13 Moreover, the pathologically low Gal-1
expression is normalized in the inactive phase of
the disease after treatment.13 We have concluded
that deﬁcient Gal-1 production and consequently,
resistance to the immunoregulatory action of extra-
cellular Gal-1 in lupus T-cells may be a pathogenic
factor in SLE.
Theories on possible relation between galectin-1
and T-cell abnormalities in SLE
T-cell pathology in SLE is very complex, including
widespread signal transduction alterations,7,56
decreased threshold of activation,7,56 defective pro-
liferation7,56 and impaired cell viability,7,56 in par-
allel with an increased survival and activity of
autoreactive, proinﬂammatory T-cell clones, and
defective Treg function57,58 (Figure 2). The ques-
tion remains how Gal-1 may contribute to SLE
pathogenesis and which points of T-cell function
may be aﬀected by Gal-1.
Lipid rafts are one of the crucial regulatory elem-
ents of signal transduction, as they reorganize the
key signalling elements to the appropriate proxim-
ity for communication between the T-cell receptor
(TCR), its co-activators, such as CD28, and non-
receptor tyrosine kinases such as ZAP70 and Lck,59
all required for the initiation of T-cell activation. In
healthy cells, co-stimulation signals are required to
induce raft organization at the contact site to com-
mence early signalling events.60 In SLE T-cells,
lipid rafts are permanently highly polarized and
clustered even under unstimulated conditions,
which leads to a lower activation threshold of
these cells.61 The importance of raft organization
in lupus pathology was demonstrated in an SLE
murine model, showing that crosslinking of GM1
with cholera toxin B (CTXB) augmented the dis-
ease by further strengthening lipid raft aggregation,
while the disruption of raft integrity through deple-
tion of cholesterol slowed down disease progres-
sion.62 Gal-1 may be an element of the abnormal
lipid raft clustering found in lupus T-cells. Gal-1 is
known to counteract CD28 co-activation-triggered
lipid raft organization as part of its anti-prolifera-
tive eﬀect.24 This ability is likely dependent on
cross-linking of GM1,24,27,47 an abundant compo-
nent of lipid rafts that is further upregulated during
activation.63,64 The exact function of GM1 is still
unclear, but most likely it is responsible – along
with cholesterol – for scaﬀolding the raft by
decreasing lateral mobility in the area of the
immunological synapse.65 Normally, lipid raft
aggregation should not commence until cell–cell
contact is established and early activation signalling
has been initiated.66,67 It is reasonable to hypothe-
size that Gal-1 deﬁciency, through insuﬃcient
cross-linking of GM1, fails to counteract the exag-
gerated raft reorganization in lupus activated T-
cells.61,68 This could be explained by the lower
amount of intracellular Gal-1, due either to a
defect in its production13 or to a limited response
to Gal-1 because of the altered cell surface glyco-
sylation of lupus T-cells (unpublished results).
Another major functional disruption that acts in
concert with pre-assembled lipid rafts to amplify
the reactiveness of SLE T-cells is the faulty con-
struction of the TCR-CD3 complex, which leads
to dysregulated downstream signalling. In healthy
T-cells, several important signalling components
are recruited to the TCR-CD3 complex when
early antigen signalling triggers lipid raft formation
at the contact site.59 However, with preformed rafts
already in place on SLE T-cells, a more rapid and
powerful signalling cascade can be triggered, begin-
ning with a more pronounced calcium
response.68,69 As an early, indispensable step of
signal transduction, the CD3 z chain is phosphory-
lated by Lck kinase through its immunoreceptor
tyrosine-based activation motifs (ITAMs), followed
by the recruitment of ZAP-70 to the TCR-CD3
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complex.70 Phosphorylated ZAP-70 will then
propagate the signal by phosphorylating linker of
activation for T-cells (LAT) and SH2-domain-con-
taining leukocyte protein of 76 kDa (SLP-76),
transmitting the signal to downstream compo-
nents.70 In contrast, in SLE, the expression of the
TCR z chain is severely diminished in about half of
patients due both to decreased stability and
Figure 2 Signal transduction in SLE T-cells and possible targets for Gal-1 action.
High GM-1 content plays a role in keeping lipid rafts polarized and lowers the activation threshold of the cells.61 Due to a
disturbed TCR with FcRg in place of CD3z,71–74 the TCR signal is carried by Syk kinase instead of ZAP-70.75 This leads to
abnormally high Ca2þ response, which initiates CD40L overexpression80 and may lead to heightened mitochondrial membrane
potential (m),103 though a causal link is questionable, as treatment with rapamycin normalizes Ca2þ flux but not mitochondrial
membrane potential.104 On the other hand, Syk activation weakens the JNK-c-JUN-AP-1 pathway and leads to low IL-2 expres-
sion83,84 as well as dampening the apoptotic effect of Gal-1.85 High m drives differential expression of mTOR complex 1 and 2
in a way that skews the differentiation of T cells towards the Th1 or Th17 lineage,96 and induces HRES/Rab4 expression, leading to
further degradation of CD3z.104 High m also causes ATP depletion, which favours cell death by necrosis,105,106 creating more
autoantigens that perpetuate SLE pathology. Thick arrows denote heightened expression or signal strength; thin arrows denote
lowered expression or signal strength. (a) Gal-1 is known to inhibit lipid raft polarization,24 probably through cross-linking of GM-
1.27 (b) Gal-1 can contribute to the Th17/Treg imbalance by specifically taking Th17 cells into apoptosis,94 and rGal-1 treatment
normalized Treg levels in an animal model of SLE.19 (c) The JNK-c-Jun-AP-1 pathway is indispensable for the transmission of the
Gal-1 apoptotic signal, and its low activity in SLE T-cells may be a cause of the unresponsiveness of these cells to Gal-1. m:
mitochondrial membrane potential; AP-1: activator protein-1; APC: antigen presenting cell; ATP: adenosine triphosphate;
AutoAG: autoantigen; Gal-1: galectin-1; JNK: c-Jun N-terminal kinase; mTORC1/2: mTOR complex 1/2; NFAT: nuclear
factor of activated T-cells.
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increased degradation of abnormal splice vari-
ants.71–73 The defunct CD3 z is replaced by the g
chain of FcR,74,75 and consequently the activation
signal is diverted from the normal ZAP-70 route to
Syk,75 a pathway not existing in physiological T-
cells.76 Since early signal transduction in Gal-1
induced apoptosis also includes Lck and ZAP-
70,39 and Gal-1 sensitivity in these cells is compro-
mised,13 the dysfunctional TCR signal transduction
pathway and diminished Gal-1 eﬀectiveness may be
connected.
The exchange of CD3 z-ZAP-70 to the FcRg-Syk
pathway results in a hundred-fold more eﬀective
signal relay,77 which leads to abnormally quick
and strong calcium response.78 The high Ca2þ
level activates downstream signal elements such as
the phosphatase calcineurin, which dephosphory-
lates and thereby activates the transcription factor
nuclear factor of activated T-cells (NFAT).79
Consequently, expression of target genes, such as
CD40L (CD154), is upregulated. Indeed, CD40L is
overexpressed on SLE T-cells80,81 and probably
plays a role in maintaining autoreactive B-cell func-
tions.81 Moreover, CD40L is important in guiding
the diﬀerentiation of T-cells towards the inﬂamma-
tory Th17 subset, a central T-cell type in SLE
pathogenesis.82 Another consequence of the
ZAP70–Syk exchange is the decreased activation
of the JNK-c-Jun-AP-1 pathway,83 which leads to
the downregulation of genes whose promoters
require the simultaneous binding of multiple tran-
scription factors for activation, most importantly of
IL-2.84 Lack of IL-2 signiﬁcantly contributes to the
impaired proliferative activity and the increased
susceptibility to apoptosis of lupus T-cells. In this
regard, it seems relevant that the apoptotic eﬀect of
Gal-1 on the Jurkat T-cell line is mediated by a
signalling pathway eventually leading to c-Jun-N-
terminal Kinase (JNK) activation via phosphoryl-
ation of PKC-d, PKC-y, MAPK-kinase-kinase-4,
and the consequent phosphorylation of JNK.85
JNK phosphorylates c-Jun, a component of the
transcription factor AP-1, which induces the
expression of the proapoptotic protein Bad and
the suppression of the antiapoptotic protein
Bcl2.85 Importantly, all these eﬀects of Gal-1 are
dependent on the presence of a functional TCR-
CD3-ZAP70 complex.85 Since the same steps in
the MAPK-JNK-AP-1 pathway have been
described as being deﬁcient in lupus T-cells,83 it is
plausible to hypothesize that insuﬃcient Gal-1
eﬀect, probably due to an arrest in its activities at
the dysfunctional CD3-ZAP70 point, could play a
part in the altered viability of T-cells in SLE.
Decreased IL-2 production in SLE results in
reduced proliferation of all T-cell subsets, particu-
larly of Treg cells, whose diﬀerentiation and activ-
ity are critically dependent on IL-2.86 Accordingly,
SLE Treg cells display deﬁciency in both number
and functionality,87,88 and a recent study has found
that addition of low amounts of IL-2 can selectively
restore Treg cell functions in vitro.89 Healthy, rest-
ing Treg cells express Gal-1, and Gal-1 level is ele-
vated upon their activation, while reduction or
deﬁciency in Gal-1 expression results in diminished
Treg cell function.35,90 SLE eﬀector T-cells produce
reduced amounts of Gal-1,13 and these cells also
exhibit reduced sensitivity to Gal-1 mediated apop-
tosis in vitro.13 Whether Treg cells from SLE
patients also express decreased amounts of Gal-1
has to be clariﬁed. If so, Gal-1 deﬁciency in Treg
cells may contribute to impaired Treg function and
hence to dysregulated eﬀector T-cell activity. A spe-
ciﬁc Treg subtype, the IL-10 producing FoxP3
Tr1 cells, are readily induced by Gal-1. These
cells exert an immunoregulatory function mediated
by the secretion of IL-10, by the apoptotic eﬀect of
the surface molecule programmed death-1 (PD-1),
and by tolerance induction due to lack of expres-
sion of the co-stimulatory molecule CD40L.91
Notably, Facciotti et al. have recently shown that
this particular regulatory T-cell subtype fails to
exert its suppressive function in SLE patients, and
this defect potentially contributes to B-cell hyper-
activity in lupus.91
Multiple studies have found that SLE patients
show a distinct and signiﬁcant cytokine imbalance
that skews the diﬀerentiation of T-cells towards the
inﬂammatory Th17 subset.57,58 Another major
source of Th17 is double negative (CD4 CD8)
T-cells, which were found abundantly in the circu-
lation in SLE patients.92 These cells likely originate
from CD8þ T-cells that undergo epigenetic block-
age of the CD8 gene cluster by adenosine 3’5’ cyclic
monophosphate (cAMP) response element modula-
tor (CREM) driven trans-repression.93 They pro-
duce IL-17 and have receptors for IL-23, and are
thus regarded as being functionally similar to Th17
cells.92 Gal-1 exerts an apoptotic eﬀect on Th17
cells94 that would potentially counteract this imbal-
ance, but this cytotoxicity requires the endogenous
expression of Gal-1 in the target T-cell, which is not
the case in lupus.13
Mammalian target of rapamycin (mTOR) is a
central checkpoint molecule in intracellular signal
transduction.95 In SLE, mTOR activity is abnor-
mally high due to mitochondrial hyperpolarization
or an overactive PI3-kinase-Akt pathway.96,97 The
PI3-kinase-Akt signalling cascade is regulated by
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phosphatase and tensin homolog (PTEN), which is
defective in both expression and activity.98 As
potential causes of decreased PTEN expression,
inhibition of PTEN mRNA translation by micro-
RNAs miR-7, miR-21 and miR-22 has been pro-
posed.99,100 Although most data on PTEN in lupus
have been obtained on B-cells, it is interesting that
miR-22 also down-regulates Gal-1 production,101
and therefore the overproduction of this
microRNA may have multiple and potentially
coordinated eﬀects on T-cell activation and viabil-
ity in lupus.
Calcium signalling can also be regulated by Gal-
1. It is known that Treg-derived Gal-1 cross-links
GM1 ganglioside on eﬀector T-cells,102 and that
Gal-1–GM1 cross-linking triggers Ca2þ inﬂux via
the calcium channel transient receptor potential
channel-5 (TRPC5) in the eﬀector cells.102 The
resulting elevation of intracellular Ca2þ concentra-
tion initiates a signalling cascade, which then cul-
minates in the suppression of the proliferation of
eﬀector T-cells.27,102 It is conceivable that impaired
Gal-1–GM1 triggered suppression of eﬀector T-cell
proliferation by Tregs is also a potential mechanism
in SLE pathogenesis.
In summary, several steps have been identiﬁed in
dysfunctional SLE T-cell signalling which involve
the mechanism of action of Gal-1. Some hypotheses
proposed in this review may initiate further research
to prove or discard the involvement of Gal-1 in the
intracellular pathogenetic processes in lupus.
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